Clinical trials: Allogeneic Transplant
Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
This phase I trial studies the side effects of donor natural killer (NK) cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory).
- Conditions
- Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04220684
- Testing
- Cytarabine Hydrochloride, Fludarabine, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Sumithira Vasu
Acute Leukemia, High Risk, Myelodysplastic Syndromes, High Risk
A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.
This clinical study is testing a new way to improve stem cell transplants for adults with high-risk blood cancers, such as leukemia or myelodysplasia, who do not have a suitable donor.
- Conditions
- Acute Leukemia, High Risk, Myelodysplastic Syndromes, High Risk, Hematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor
- Trial name
- ECT-001-CB-013 (NCT07301866)
- Testing
- ECT-001-CB
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
CAR-T Cell Therapy, RSV Immunization
RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients
This study evaluates whether the RSV vaccine Abrysvo can produce an antibody response in patients with blood cancers who have previously received a hematopoietic stem cell transplant (HSCT) or CAR-T cell therapy.
- Conditions
- CAR-T Cell Therapy, RSV Immunization, Bone Marrow Transplant - Autologous or Allogeneic
- Trial name
- NCT07296120
- Testing
- Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cooper Health System
Stem Cell Transplant, Allogeneic
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
Participants are being asked to take part in this study because treatment of his or her disease requires a stem cell transplant.
- Trial name
- EXCESS (NCT01189786)
- Testing
- CliniMACS CD34 Reagent system
- Where
- 2 sites in United States
- Volunteers
- 241 people
- Sponsor
- Baylor College of Medicine
Acute Leukemia, Myeloid Leukemia
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
This is a multicenter, open-label study in people aged 18 and older with relapsed or refractory acute myeloid leukemia. It has two parts.
- Conditions
- Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07157514
- Testing
- 131I-apamistamab, Fludarabine, Cyclophosphamide
- Volunteers
- 306 people
- Sponsor
- Actinium Pharmaceuticals
Stem Cell Transplant Complications, Myeloma
Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT
As the average age of individuals undergoing stem cell transplant continues to increase, challenges associated with balancing the side effects of cancer treatments while also managing other medical conditions develop.
- Conditions
- Stem Cell Transplant Complications, Myeloma, Lymphoma, Allogeneic and Autologous Stem Cell Transplant
- Trial name
- NCT04194840
- Testing
- physical therapy consult, Cognitive Assessment, Cancer Aging Research Group (CARG) assessment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Case Comprehensive Cancer Center
Immunoglobulin Prophylaxis, Cytomegalovirus Infections
Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Human cytomegalovirus (CMV) is a globally prevalent, human-specific herpesvirus characterised by a lifelong latency after primary infection, an often asymptomatic reactivation and affecting up to 100% of adults based on region…
- Conditions
- Immunoglobulin Prophylaxis, Cytomegalovirus Infections, Allogeneic Hematopoietic Stem Cell Transplantation, Transplant-Related Disorder
- Trial name
- NCT07013370
- Testing
- Anti-CMV immunoglobulins [Megalotect (R)]
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Antonello Di Paolo, M.D., Ph.D.
Allogeneic Stem-Cell Transplant
Early Chimerism Following Allogeneic Stem-Cell Transplant
Allogeneic stem cell transplant (allo-SCT) is a common treatment for variety of blood cancers. To determine how many cells are from the donor after transplant, doctors complete a "chimerism analysis" or a test of participant…
- Trial name
- NCT03689907
- Testing
- Chimerism Evaluation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Acute Graft-versus-Host Disease, Allogeneic Stem Cell Transplant
Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease
Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease (GVHD).
- Trial name
- NCT01521039
- Testing
- Blood samples
- Where
- United States
- Volunteers
- 259 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
The purpose of this study is to reduce the risk of cancer relapse by giving a donor lymphocyte infusion (DLI) to boost the immune system early after a stem cell transplant so that leukemia cells that escaped chemotherapy can be…
- Conditions
- Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Trial name
- NCT03939585
- Testing
- Cellular therapy product
- Where
- United States
- Sponsor
- Leland Metheny
Cytomegalovirus (CMV)-Positive Recipients, Allogeneic, Hematopoietic Cell Transplant (HCT)
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
The purpose of the study was to evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through 1 year post-transplant.
- Trial name
- HELIOS (NCT01877655)
- Testing
- ASP0113
- Where
- 83 sites in United States, Australia and 9 more
- Volunteers
- 514 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Allogeneic Hematopoietic Cell Transplant
A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant
This study is to evaluate safety and tolerability of a therapeutic vaccine, ASP0113, in subjects undergoing allogeneic HCT. The occurrence of CMV viremia and immunogenicity are also assessed.
- Trial name
- NCT01903928
- Testing
- ASP0113
- Where
- 2 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Inc
CD19+ Malignancies: Relapse Post-allogeneic Transplant
CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation
Eligible patients will receive escalating doses of 4G7-CARD T-cells paralleling clinical standard of care with unmanipulated donor lymphocytes. There are 3 intra-patient dose levels planned.
- Trial name
- CARD (NCT02893189)
- Testing
- Infusion of modified CAR19 T-cells (4G7-CARD T-cells)
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- University College, London
Myelodysplastic/Myeloproliferative Neoplasm, Steroid Refractory GVHD
Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm
This is a single participant study of decidual stromal cells (DSC) for the treatment of steroid refractory graft-versus-host disease (GVHD) in a patient with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN).
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Steroid Refractory GVHD, Allogeneic Hematopoietic Cell Transplant
- Trial name
- DSC-SR (NCT04926194)
- Testing
- Decidual stromal cells (DSC)
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
Allogeneic Stem Cell Transplant, Viral Infection
Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant
The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to prevent viral infections that may happen after allogeneic stem cell transplant.
- Trial name
- NCT03883906
- Testing
- Viral Specific T-cells (VSTs)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Leukemia, Lymphoma
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
The main purpose of this study is to assess the effects of cyclophosphamide (cytoxan) in the post transplant setting to prevent onset of acute graft-versus-host disease (GVHD).
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- NCT02065154
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Alabama at Birmingham
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia
Patients with acute leukaemia requiring induction or consolidation chemotherapy and those requiring a haematopoietic stem cell transplant are at high risk of fever and infection when they have low white cell counts (neutropenic…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Haematopoietic Stem Cell Transplant, Autologous, Haematopoietic Stem Cell Transplant, Allogeneic
- Trial name
- PIPPIN (NCT03429387)
- Testing
- FDG-PET/CT, Conventional CT
- Where
- 2 sites in Australia
- Volunteers
- 147 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Venous Allogeneic Transplant, Occlusive Peripheral Arterial Disease
Assessment of the Sub-gonal Arterial Revascularization of the Lower Limbs in Critical Ischemia by Venous Allograft Stored at + 4 ° C (ERAV)
The main objective of this study is to assess the 2-year survival with salvage of the lower limb of patients who have undergone subgonal bypass grafting by venous allograft in the treatment of Occlusive Peripheral Arterial…
- Trial name
- ERAV (NCT05101512)
- Testing
- Questionnaires on quality of life after surgery
- Where
- France
- Volunteers
- 150 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Graft Versus Host Disease, Allogeneic Hematopoietic Cell Transplant Recipient
Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD
Chronic graft versus host disease (cGVHD) is a common complication of bone marrow or hematopoietic cell transplant from another person (allogeneic transplant).
- Trial name
- NCT01911039
- Testing
- Regulatory T Cells
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Laura Johnston
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
This phase I/Ib trial studies the side effects and best dose of ipilimumab or nivolumab in treating patients with cancers of the blood and blood-forming tissues (hematologic cancers) that have returned after a period of…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT01822509
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)